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The initial evaluation of patients with suspected deep vein thrombosis includes the use of biomarkers reflecting
activation of the coagulation system. However, the thromboembolic process and neighboring inflammatory
responses also affect endothelial cells, and endothelial cell markers may therefore be altered by the disease. In
the present population-based single-center study, we investigated the plasma levels of the endothelium-specific
biomarkers soluble E-selectin and endocan in a consecutive and unselected group of 120 patients admitted to
hospital for suspected deep vein thrombosis. Blood samples were collected when patients arrived at the hospital.
DVT patients showed evidence for an acute phase reaction with increased serum C-reactive protein levels, but this
was similar to many other patients admitted with suspected but not verified thrombosis. Plasma endocan and
E-selectin levels did not differ between patients with thrombosis, healthy controls and the patients without verified
thrombosis (i.e. patients with other causes of their symptoms, including various inflammatory and non-inflammatory
conditions). However, the combined use of endothelial biomarkers, C-reactive protein and D-dimer could be used
to identify patient subsets with different frequencies of venous thrombosis. Thus, analysis of plasma biomarker
profiles including endothelial cell markers may be helpful in the initial evaluation of patients with deep vein
thrombosis.
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The development of venous thromboembolism (VTE),
i.e. deep vein thrombosis (DVT) and pulmonary em-
bolism (PE), represents a complex interaction between
inflammatory pathways as well as the coagulation sys-
tem, and it involves a wide range of cells including
various leukocytes, platelets and endothelial cells (Fox &
Kahn 2005; Hou et al. 2012; Coleman & Wakefield 2012).
The clinical presentation of DVT varies, and range from
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in any medium, provided the original work is pto a disease with very few or no noticeable symptoms
(Fox & Kahn 2005; Hou et al. 2012). The clinical handling
of patients with suspected DVT can be challenging, and
several molecular as well as cellular biomarkers have been
suggested for the initial diagnostic handling of these
patients (Hou et al. 2012; Coleman & Wakefield 2012).
The biomarkers most extensively studied are molecular
markers suggesting activation of the coagulation system
(i.e. platelet activation, activation of the coagulation fac-
tor system) or various cellular or molecular markers indi-
cating an inflammatory process (Hou et al. 2012; Coleman
& Wakefield 2012). However, endothelial cells are also
affected by and contribute to the development of DVT,
and in the present study we compared systemic levels of
endothelial cell markers in patients with diagnosed and
suspected DVT. We then investigated the plasma levelss an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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regarded as endothelial cell-specific. A possible future
strategy for the evaluation of patients with suspected ven-
ous thrombosis might be to evaluate biomarker profiles
instead of single markers.
The development of a diagnostic biomarker panel is a
multistep process, as illustrated by the biomarker panel
developed for diagnostic and prognostic use in acute graft
versus host disease after allogeneic stem cell transplant-
ation (Paczesny et al. 2009; Harris et al. 2012; Ferrara et al.
2011; Levine et al. 2012). The first step was to compare
the levels of a large number of biomarkers between con-
trasting groups; the authors then compared the plasma
levels of a large number of biomarkers (120 proteins) for
two relatively small groups (21 patients each) with severe
GVHD and without GVHD (Paczesny et al. 2009). The
authors identified biomarkers showing significant differ-
ences between these two groups (35 biomarkers). In the
second step they selected 23 biomarkers for further evalu-
ation based on defined criteria, including the potential
biological relevance to disease development. Thirdly, 8
selected biomarkers were tested in a large cohort of 424
unselected patients, and a panel consisting of 4 biomarkers
was then found to be optimal for diagnostic and prognos-
tic evaluation. Finally, in the last part of these studies two
organ-specific biomarkers were combined with the 4 pre-
vious biomarkers to improve the diagnostic and prognos-
tic accuracy of the panel (Harris et al. 2012; Ferrara et al.
2011; Levine et al. 2012). A similar initial strategy was also
used to design a prognostic biomarker panel for patients
with suspected severe sepsis, and these authors used a
panel of 9 mediators in their final analysis (Shapiro et al.
2009). Several other studies also suggest a multibiomarker
approach in sepsis prognostics (Skibsted & Shapiro 2014;
Wong et al. 2014; Wong et al. 2012). The possible use of
biomarker panels in the diagnosis of venous thrombo-
embolic disease should probably follow a similar strategy,
and the present study represents a first step in a similar
process where we investigate the possible use of biologic-
ally relevant biomarkers (i.e. endothelial cell markers) in
clinically relevant contrasting groups, i.e. patients with
and without verified deep vein thrombosis in a group of
unselected patients admitted to hospital with suspected
thrombosis.
Materials and methods
Study population
The study was approved by the local Ethics Committee
(REK Vest Norway, nr. 27.03) and patients were included
after written informed consent. We included a total of 120
consecutive and thereby unselected patients with sus-
pected DVT referred by primary health care physicians to
the Emergency Department at Haukeland University
Hospital. The hospital is a primary care center for allpatients with suspected DVT within a defined geo-
graphic area; our study should therefore be regarded as a
population-based cohort study. Our study did not include
in-hospital patients who developed DVT during their hos-
pital stay for other disorders.
All patients followed a standardized evaluation algo-
rithm; patients with positive D-dimer (≥0.5 mg/L) and/or
high Well’s score (≥2) were referred to compression ultra-
sound and ultimately to contrast venography if the
ultrasound examination was inconclusive or a leg vein
thrombosis was suspected. Control samples were ob-
tained from 19 healthy individuals; this group included 19
adults with no disease symptoms during the last week, no
present disease and none of them had taken any drugs
during the last week. Due to technical reasons only plasma
samples were available for 117 of the patients. Endocan
levels were then investigated for all 117 patients, whereas
due to technical reasons E-selectin levels were investigated
for overlapping subsets of consecutive/unselected patients
by ELISA and/or Luminex technology (explained in detail
below in the chapter Cytokine analyses).
None of the patients without thrombosis were readmit-
ted to hospital during the following 4 weeks with increas-
ing or persisting symptoms requiring a new evaluation
due to suspected DVT.
Preparation and preservation of plasma samples
Peripheral venous blood samples were collected into
Vacutainer 9NC tubes (Becton-Dickenson, San Jose, CA)
with citric acid as anticoagulant. Samples were thereafter
transferred to plastic tubes without additives and centri-
fuged twice at 200 g for 15 minutes at room temperature.
Centrifugation was performed within 120 minutes from
sampling. The plasma supernatants were finally transferred
to cryotubes, frozen immediately and stored at −80°C until
analyzed.
Cytokine analyses
Soluble E-selectin (R&D Systems; Abingdon, UK; the last
98 consecutive patients) and endocan levels (Lunginnov,
Pasteur Institute, Lille, France; 117 patients examined)
were determined by ELISA analyses strictly according to
the manufacturers’ instructions. These results were used
in the clustering analyses.
E-selectin levels were in addition analyzed by Luminex
analyses (R&D Systems) for the first 89 consecutive pa-
tients and for 20 healthy controls. These results were used
for the comparison between healthy controls and between
subsets of patients.
All results are presented as the mean of duplicates.
Statistical and bioinformatical analyses
Statistical analyses were performed using Graph Pad
Prism 5 (Graph Pad Software, Inc., San Diego, CA, USA).
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for correlation analyses, and the Mann-Whitney’s rank
sum test to compare different groups; p-values <0.05 were
regarded as statistically significant. Unless otherwise stated
in the text, the p-values were not corrected for the num-
ber of comparisons. SPSS version 20.0 (SPSS Inc., Chicago,
Illinois, USA) was used for logistic regression analysis.
Bioinformatical analyses were also performed using the
J-Express 2012 analysis suite (MolMine AS) (Stavrum et al.
2008).
Results
DVT was diagnosed in a minority of patients admitted to
hospital with suspected thrombosis
The large majority of the patients were referred to the
hospital due to recent development of pain localized to
the leg, pain when palpating the leg and unilateral edema
of the lower extremity. The initial diagnostic evaluation
of the 120 patients included clinical examination, plasma
D-dimer and ultrasound/Doppler examination of the af-
fected extremity; venography was only performed if the
initial examination was inconclusive and a deep leg vein
thrombosis was suspected. The D-dimer level was normal
in 32 of the 120 patients. Twenty-three patients were not
examined by ultrasound or venography; all of them having
a normal D-dimer test and Wells score less than 2. Venog-
raphy was performed in 14 patients and was positive for 2
of them. Other conditions than DVT were diagnosed by
the clinical physician at the Emergency Department based
on an overall evaluation of the patient. Infections were pre-
dominantly skin infections. The most important clinicalTable 1 The final diagnoses of patients admitted to hospital
Diagnosis
Number of
patients
(n = 120)
Temperature
(°C) BP (systolic)
Deep vein thrombosis 28 36.9 (36.2-38.8) 146 (95–192)
Involving the iliac vein 10
Involving femoral vein 13
Only involving the leg
and popliteal vein
5
Superficial thrombophlebitis 6 37 (36.5-37.5) 146 (129–204
Sterile inflammation including
trauma/muscular bleeding,
ruptured Baker’s cyst, arthritis,
malignant diseases without
thrombosis
33 36.9 (35.9-38.1) 150 (91–202)
Infections 12 37.2 (36–38.5) 137 (100–169
Venous stasis 8 36.6 (36–37.5) 143 (99–183)
Other conditions without
inflammation including
musculoskeletal pain and
neurological disorders
33 36.9 (36–38) 139 (104–175
Clinical data for each diagnosis are presented as median and range.data of the patients are summarized in Table 1. Median
age of our patients was 68 years (range 19–101 years) with
69% females.
Only 28 patients were diagnosed with thrombosis; 10
patients with high thromboses involving the iliac vein, 13
patients with femoral vein and lower thrombosis, whereas
a minority of 5 patients was diagnosed with leg vein
thrombosis. Three of the 28 patients with DVT were also
diagnosed having PE.
Plasma endocan and E-selectin levels do not differ
between patients with and without DVT
We compared plasma endocan and E-selectin levels for pa-
tients with DVT, patients without verified DVTand a group
of 19 healthy controls. The patient results are presented in
Figure 1 and the statistical analyses are summarized in
Table 2; as will be described in detail below there was a
large degree of overlap between patient subsets (Figure 1)
and also between patients and controls (data not shown).
Endocan plasma levels were determined for all pa-
tients. When comparing the overall results the endocan
levels showed a significant correlation with serum CRP
(p = 0.0234) but not with D-dimer levels (p = 0.22). Plasma
E-selectin levels were determined by Luminex technology
for the first 89 consecutive/unselected patients, and
in contrast to endocan the E-selectin levels did not
show any significant correlation with CRP (p = 0.063)
or D-dimer levels (p = 0.68). We also compared endocan
and E-selectin (Luminex analyses, the 89 first consecutive
patients) plasma levels for patients with and without deep
vein thrombosis, but none of the two biomarkers differedwith suspected deep vein thrombosis
Heart rate WBC(×109/L)
HB
(g/dL)
TPK
(×109/L)
Wells
score
81 (54–114) 7.8 (3.8-18.3) 14.1 (9.8-17.8) 220 (115–401) 3 (1–6)
) 74 (63–97) 9.3 (6.8-13.8) 14.5 (12.7-15) 257 (76–312) 1.5 (1–3)
81 (50–110) 8.1 (4.7-13.3) 13.9 (10.1-16.3) 292 (209–507) 1 (−2 - 4)
) 86 (100–169) 8.7 (5.8-14.1) 13.4 (9.7-15) 301 (200–409) 1 (−1 - 2)
73 (53–104) 6.9 (4.2-12.4) 14 (10–15.9) 280 (104–528) 1.5 (0–3)
) 73 (46–96) 7.2 (2.1-13.5) 14 (8.6-16.6) 267 (179–398) 1 (−2 - 3)
Figure 1 Plasma endocan (left) and E-selectin (middle; Luminex analyses for the first 89 consecutive patients) levels and serum CRP
levels (right) in patients admitted to hospital with suspected DVT; a comparison between subsets of patients with suspected thrombosis.
We investigated a group of 120 patients. The patients were classified as described in Table 1. Thrombophlebitis was defined as clinical signs of a
local inflammatory reaction corresponding to a subcutaneous vein of the affected limb, infection means clinical and laboratory evidence for a
local infection corresponding to the affected lower limb, and an inflammatory condition means clinical and laboratory findings consistent with a
local sterile inflammation of the affected limb (e.g. a ruptured Baker’s cyst).
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more, neither endocan nor E-selectin (Luminex analyses,
the first 89 consecutive patients) showed any significant
difference when comparing patients with iliac vein throm-
boses (n = 10) to patients with thromboses only involving
the lower veins (p = 0.19 and p = 0.87 respectively). Finally,
variation ranges for endocan as well as E-selectin (Luminex
analyses, the first 89 consecutive patients) showed con-
siderable overlap when comparing patients with throm-
bosis, patients without thrombosis and healthy individuals
(Figure 1).
We also did the same statistical analyses for E-selectin
levels determined by ELISA analyses for the last 98 con-
secutive patients, and the results were similar for both
subsets (data not shown).
Based on the present sample size and the observed
plasma levels for patients with and without verified
thrombosis, there is a 20% chance (statistical power 20%;
1-p = 0.8) of not detecting a true difference and a 5%
chance of detecting a false difference (α = 0.05) if the obser-
vations (i.e. Δμ) differ with endocan 0.7 pg/ml, E-selectin
8400 pg/ml, D-dimer 3.7 μg/ml and CRP 21 μg/ml.
Plasma endocan and E-selectin levels in various patient
subsets admitted to hospital with suspected deep vein
thrombosis
We compared the plasma levels of soluble endocan and
E-selectin for the various patient subsets admitted with
suspected deep vein thrombosis, and each subset was also
compared with the healthy controls. The overall results
are presented in Figure 1 and the statistical comparisonsare presented in detail in Table 2. There was a large over-
lap in plasma endocan levels between the various groups.
The endocan levels for DVT patients showed a difference
of borderline significance compared to patients with ster-
ile inflammation (p = 0.0407). Patients with thromboses
also differed significantly from the healthy controls, but
this was also true for the other patient subsets except pa-
tients with venous stasis (data not shown).
Plasma E-selectin levels were investigated only for an
unselected/consecutive subset of patients (Luminex ana-
lyses, the first 89 consecutive patients). The levels in
DVT patients did not differ significantly from any other
patient subset (Figure 1, Table 2). We then observed
only two differences of borderline significance in plasma
E-selectin levels when patients with infections were
compared with (i) patients with sterile inflammation
(Table 2, p = 0.0499) and (ii) with the healthy controls
(data not shown). Similar results were seen when we an-
alyzed the E-selectin levels measured by ELISA analyses
for the 98 last consecutive patients (data not shown).
Finally we compared CRP levels for patient subsets and
for healthy controls (Figure 1, Table 2). All patient subsets
showed evidence for an acute phase reaction compared
with healthy controls, and DVT patients differed signifi-
cantly only from the patients without clinical evidence of
inflammation.
Combined analysis of endocan, E-selectin, D-dimer and
CRP in the diagnosis of DVT
We used unsupervised hierarchical clustering for a com-
bined analysis of these parameters; all these analyses
Table 2 Comparison of serum CRP, plasma endocan and plasma E-selectin levels (luminex analyses, the 89 first
consecutive patients) in patients admitted to hospital with suspected deep vein thrombosis
Thrombophlebitis Sterile inflammation Infection Venous stasis Other causes withoutinflammation
ENDOCAN LEVELS - COMPARISON BETWEEN VARIOUS PATIENT SUBSETS (n = 117)
Deep vein thrombosis (n = 28) 0.5723 0.0407 0.8479 0.1058 0.1066
Thrombophlebitis (n = 6) 0.6558 0.3736 0.2284 0.5725
Sterile inflammation (n = 30) 0.0818 0.0230 0.8742
Infection (n = 12) 0.1770 0.1435
Venous stasis (n = 8) 0.0230
Other causes without inflammation (n = 33)
E-SELECTIN LEVELS - COMPARISON BETWEEN VARIOUS PATIENT SUBSETS (n = 89)
Deep vein thrombosis (n = 21) 0.7450 0.2485 0.0517 0.4208 0.5618
Thrombophlebitis (n = 5) 0.8271 0.1898 0.4351 0.8852
Sterile inflammation (n = 22) 0.0938 0.9813 0.5165
Infection (n = 9) 0.2359 0.0499
Venous stasis (n = 8) 0.5864
Other causes without inflammation (n = 24)
CRP LEVELS - COMPARISON BETWEEN VARIOUS PATIENT SUBSETS (n = 120)
Deep vein thrombosis (n = 28) 0.2132 0.0842 0.1693 0.1949 < 0.0001
Thrombophlebitis (n = 6) 0.7993 0.0608 0.8461 0.1396
Sterile inflammation (n = 33) 0.0097 1.0000 0.0029
Infection (n = 12) 0.0277 < 0.0001
Other causes without inflammation (n = 33)
The Mann Whitney t-test was used for the statistical comparison and the p-value is given for each statistical comparison (significant differences are marked in
bold). Thrombophlebitis was defined as clinical signs of a local inflammatory reaction corresponding to a subcutaneous vein of the affected limb, infection means
clinical and laboratory evidence for a local infection corresponding to the affected the lower limb, and sterile inflammation means a condition with local sterile in-
flammation of the affected limb (e.g. a ruptured Baker’s cyst).
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endothelial biomarkers were analyzed by ELISA analyses.
We first made an analysis only including the two endo-
thelial cell parameters together with CRP levels (Figure 2,
left part). It can be seen that the patients with DVT as
well as several patients with other diagnoses were in-
cluded in all except one of the main clusters; only a clus-
ter consisting of the 11 lower patients did not include
any of the DVT patients. We compared the levels of the
3 biomarkers for this subset with the other 87 patients
(Table 3); the endocan plasma levels were then signifi-
cantly lower than for the other 87 patients. There was a
large overlap of the variation ranges for all three bio-
markers between the 11 patients and the other 87 patients.
Thus, the cluster is defined by the overall biomarker pro-
file, but especially by relatively low endocan levels.
We did an additional clustering analysis including
endocan, E-selectin, CRP and D-dimer (Figure 2 right).
The upper main cluster consisting of 29 patients in-
cluded 18 of the 21 DVT patients, and the lower sub-
cluster of this group (patients 15–29 counted from the
top) included 15 patients and 12 of them had DVT. This
lower 15–29 subcluster was characterized by high levelsof both CRP and D-dimer. The ideal situation would be
that our biomarker profile identified two major cluster
where one of the clusters only included all DVT patients;
with regard to this our biomarker/clustering strategy
showed a specificity of 0.87 and a sensitivity of 0.86 even
though the frequency of DVT patients differed signifi-
cantly between the two major clusters (Figure 2 right part,
p < 0.001). The corresponding values for normal versus
abnormal D-dimer were sensitivity 1.00, specificity 0.38
and p = 0.003. Finally, the 29 patients in the upper main
cluster differed significantly from the lower main cluster
(patients 30–98) both with regard to endocan, CRP and
D-dimer levels and showed increased levels of all three
mediators (Table 3), but again the variation ranges showed
a large extent of overlap. The identification of two main
subsets is thus dependent on the overall biomarker profile,
but the E-selectin levels seem to be less important.
We also used an adjusted logistic regression model com-
bining endocan, E-selectin, D-dimer and CRP; this did not
detect any additional differences for any mediator.
We conclude that the combination of two endothelial
cell markers, one coagulation marker and one acute phase
reactant seems to identify a patient subset with a very low
Figure 2 Unsupervised hierarchical clustering of patients with
suspected DVT based on serum/plasma levels of Endocan, E-
selectin (ELISA analyses, the last 98 consecutive patients), CRP
and D-dimer in 98 patients. (LEFT) The clustering was based on
endocan, E-selectin and CRP. (RIGHT) The clustering was based on
endocan, E-selectin, CRP and in addition D-dimer.
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with very high probability of DVT.
Discussion
Previous studies have described that the systemic levels
of several biomarkers are altered in patients with DVT
compared with healthy controls. In the present study we
investigated plasma levels of the endothelium-specific
biomarkers endocan and E-selectin, and we describe that
combined analysis of these biomarkers (either the two
markers alone or together with D-dimer and CRP) could
be used to identify patient subsets with different fre-
quencies of DVT in a group of consecutive/unselected
patients admitted to hospital with suspected DVT.
The design of diagnostic biomarker panels will often be
a multistep process as illustrated by the diagnostic and
prognostic biomarker panel for acute GVHD (Paczesny
et al. 2009; Harris et al. 2012; Ferrara et al. 2011; Levine
et al. 2012; Shapiro et al. 2009). In our opinion a similar
strategy should be used for DVT (see the last chapter of
the Introduction), and our present study suggest that
only endocan but not E-selectin differ between patients
with verified thrombosis and various patient subsets with
symptoms due to other diseases. Our hierarchical clustering
analyses further illustrates how the use of endothelium-
specific biomarkers can be used in combination with other
markers to identify patient subsets with a high fre-
quency of thrombosis. The design of a diagnostic bio-
marker panel for patients with suspected DVT will
require both larger clinical studies than our present study
and should include a limited number of carefully selected
biomarkers (often 4–9 markers (Paczesny et al. 2009;
Harris et al. 2012; Ferrara et al. 2011; Levine et al. 2012;
Shapiro et al. 2009); in our opinion endothelium-specific
biomarkers should be included and endocan then seems
to be most relevant.
The diagnosis of DVT is usually based on a careful
clinical evaluation, D-dimer levels and visualization of
the thrombosis (Goodacre et al. 2006; Tenna et al.
2012). In our present study all patients were initially
evaluated with clinical examination, D-dimer and ultra-
sound examination; venography was performed only if
DVT was still suspected but not visualized after this ini-
tial examination. By using this diagnostic approach our
present study confirmed that DVT is diagnosed only in
a minority of patients admitted to hospital with sus-
pected thrombosis.
Table 3 Unsupervised hierarchical clustering (see Figure 2); plasma biomarker levels (median and range) for patient in
clusters with low/high frequency of DVT
Clustering: endocan, E-selectin and CRP (Figure 2 left - no DVT among patients 88–98)
Mediator Cluster patients 88-98 Cluster patients 1-87 p-value All 98 patients
Endocan plasma level 0.31 (0.15-0.65) 0.94 (0.04-6.2) < 0.0001 0.82 (0.04-6.21)
E-selectin plasma level 27741 (22191–42222) 25672 (4940–60896) ns 26286 (4940–60896)
CRP 8 (5–30) 4 (1–170) ns 5 (1–170)
Clustering: Endocan, E-selectin, CRP, D-dimer (Figure 2 right - patients 1–29 including 18 of 21 patients with DVT)
Mediator Cluster patients 1-29 Cluster patients 30-98 p-value All 98 patients
Endocan plasma level 1.02 (0.04-6.21) 0.65 (0.13-4.54) 0.0102 0.82 (0.04-6.21)
E-selectin plasma level 26276 (9971–52968) 26296 (4940–60896) ns 26286 (4940–60896)
CRP 9 (3–170) 3 (1–101) 0.0006 5 (1–170)
D-dimer 5.640 (0.90-20.00) 0.6200 (0.22-3.55) < 0.0001 0.85 (0.22-20.00)
The Mann Whitney test was used for the statistical comparison of the two patient subsets. The concentrations are given as ng/ml for endocan, pg/ml for E-selectin and
μg/ml for CRP.
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tion of the coagulation system, but there is also a local in-
flammatory response. The endothelial cells can be affected
by both these factors. For this reason we investigated
whether the endothelial cell involvement is reflected in
the systemic (i.e. plasma) levels of endothelium-specific
biomarkers, and whether these levels can be used in the
diagnostic evaluation of DVT patients. For these reasons
we examined consecutive patients admitted to hospital
with suspected deep vein thrombosis, and the plasma
levels of endothelial cell markers in DVT patients were
compared both with other patients with suspected DVT
and with healthy controls.
Endocan is an endothelium-derived proteoglycan that
shows increased plasma/serum levels in different con-
ditions, including infections and malignant diseases
(Delehedde et al. 2013; Sarrazin et al. 2006; Hatfield
et al. 2011). Our present study demonstrated that the
plasma levels of this biomarker show a considerable over-
lap when comparing healthy individuals and patients with
or without thrombosis. This overlap makes it difficult to
use endocan alone in the diagnostic evaluation of patients
with suspected deep vein thrombosis. E-selectin is also an
endothelium-derived adhesion molecule that can be de-
tected in a soluble form in serum/plasma. These levels are
decreased during febrile neutropenia, whereas increased
levels are detected during bacterial infections in immuno-
competent patients (Bruserud et al. 1996; Bruserud et al.
1995). Our present study demonstrated that this bio-
marker showed only minor variation in patients with sus-
pected venous thromboembolism.
Our present study confirmed that DVT is associated
with an acute phase reaction, including increased CRP
levels. However, this is a common characteristic for many
patients admitted with suspected DVT, and not only for
the minority who are diagnosed with a thrombosis. Manypatients with suspected DVT thus have an inflammatory
condition, and this is probably the reason why there is a
large overlap in plasma endocan and E-selectin levels be-
tween patients with diagnosed DVT and other patients
with suspected thrombosis. Plasma endocan seems to be a
part of this acute phase reactions and shows a correlation
with the CRP levels in patients with suspected DVT.
Soluble E-selectin levels has previously been investigated
once in patients with venous thromboembolic disease
(Bucek et al. 2003), and our result confirm these authors
negative findings. Systemic endocan levels have only been
investigated in one previous study only including patients
with verified pulmonary embolism (Guzel et al. 2014).
These authors described higher endocan levels in patients
with massive/submassive embolism compared with non-
massive embolism. However, we could not detect any dif-
ference between patients with iliac vein thrombosis and
patients with lower DVT. A possible explanation for this
difference between pulmonary embolism and DVT pa-
tients could be that the increased endocan levels in pa-
tients with massive pulmonary embolism are mainly due
to the embolism rather than the original thrombosis and/
or the affected circulation with pulmonary hypertension/
right heart failure.
We also did clustering analyses to investigate the com-
bined use of four biomarkers in the diagnosis of DVT:
two endothelial cell markers, one coagulation parameter
and one acute phase reactant. By this combined approach
we could identify patient subsets with very low and very
high probability of DVT. These observations suggest that
combined analyses may be useful in the clinical handling
of patients with suspected DVT, but further analysis in
future clinical studies is required.
D-dimer is the biomarker most commonly used in the
initial evaluation of patients with suspected DVT, but
none of the available biomarkers can be used alone to
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& Wakefield 2012). One possible strategy to improve the
diagnostic strength of biomarker analyses would be to
combine various biomarkers in a biomarker profile. Such
a diagnostic approach would require the development of
new bioinformatical tools suitable for routine clinical use,
but it would also require a careful evaluation of single bio-
markers with regard to their possible use as a part of a
biomarker profile.
There are several limitations of our study. Firstly, our
study is relatively small, and additional differences be-
tween patient subsets may have been detectable if a larger
number of patients had been investigated. However, in
our opinion this would have been of limited interest be-
cause of the wide variation ranges and the large overlap
between patients, this makes it unlikely that these bio-
markers will have a diagnostic/clinical relevance when
used alone. Secondly, we only included patients from out-
side the hospital mainly living at home, and we do not
know whether our approach will be useful for another pa-
tient population characterized by additional and more se-
vere diseases. Thirdly, the plasma levels of endothelial
biomarkers may be altered by DVT-predisposing condi-
tions (e.g. active cancer, pregnancy, surgery), and/or the
role of endothelial cells in the pathogenesis of DVT may
vary between the biologically heterogeneous predisposing
factors, e.g. lupus anticoagulants, genetic predisposition in
the coagulation cascade, essential thrombocythemia, par-
oxysmal nocturnal hemoglobinuria (Van Bijnen et al.
2012; Reikvam & Tiu 2012; Uitte de Willige et al. 2008).
Finally, a further evaluation of endothelial cell biomarkers
in the evaluation of patients with suspected DVT would
also require the development of bioinformatical tools that
are suitable for use in routine clinical practice.
We conclude that DVT is not associated with increased
systemic levels of endothelial cell markers (endocan,
E-selectin) compared with healthy controls, but minor
differences can be seen between subsets of patients with
verified and suspected DVT especially for endocan. Thus,
these plasma endothelial cell markers alone do not seem
to be useful in the diagnostic evaluation of patients with
suspected deep vein thrombosis, but they may become
useful in combination with other markers.
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